Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Ovid Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
12.6
208
1.5
0.39
0.57
7.25
Research and development
9.59
50
33.8
42.2
63.4
46.9
24.6
28.6
36.8
25.6
General and administrative
12.9
15
19.1
19.3
30.6
37.2
32.4
31.1
25.7
24.1
Operating expenses
22.5
65
52.9
61.4
94
84.2
57.1
59.7
62.5
49.7
Operating income
-22.5
-65
-52.9
-61.4
-81.4
124
-55.5
-59.3
-61.9
-42.4
Interest income
4.94
3.92
2.03
Other non-operating income
0.12
0.2
0.95
0.95
-0.05
1.38
6.94
35.5
25
Pre-tax income
-81
124
-54.2
-52.3
-26.4
-17.4
Income tax
0
0
0
0
1.33
0
0
0
0
Net income
-22.4
-64.8
-52
-60.5
-81
123
-54.2
-52.3
-26.4
-17.4
EBITDA
-22.5
-64.9
-52.8
-61.2
-81.1
124
-55
-58.7
-61.3
-42.2
EPS, basic
-2.28
-3.35
-2.11
-1.39
1.78
-0.77
-0.74
EPS, diluted
-2.28
-3.35
-2.11
-1.39
1.76
-0.77
-0.74
Shares, basic (weighted)
9.84
19.3
24.6
58.5
67.5
70.4
70.6
Shares, diluted (weighted)
9.84
19.3
24.6
58.5
68.1
70.4
70.6
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
51.9
87.1
36.5
41.9
72
188
44.9
27
26.3
13.2
Short-term investments
5.01
34.8
0
84.1
78.8
26.8
56.5
Other current assets
0.22
1.46
2.17
1.94
2.67
2.68
2.38
3.76
2.87
4.73
Total current assets
52.4
88.6
44.3
79.8
74.8
190
131
110
55.9
74.4
Property, plant and equipment
0.04
0.05
0.07
0.07
0.14
0.24
1.15
0.77
0.43
0.25
Lease right-of-use assets
0
14.9
13.9
12.8
11.6
Intangible assets
0.11
0.12
0.39
0.47
0.32
0.16
0.22
0.2
0.1
0
Long-term investments
0
1.63
5.62
17.6
21
20.8
Other non-current assets
0.17
0.12
0.39
0.47
0.32
0.26
0.26
0.21
0.09
0
Total assets
53
89.5
47.6
80.8
75.9
195
155
144
92.2
151
Accounts payable
0.86
2.03
3.76
3.26
5.45
7.13
1.95
3.7
3.19
1.96
Accrued liabilities
2.88
4
5.09
7.27
12
7.67
4.5
6.52
5.99
4.9
Deferred revenue
2.21
0
Total current liabilities
3.73
6.02
8.84
10.5
22.1
14.8
6.99
11.5
10.5
8.29
Lease liabilities
0
16
14.8
13.4
12
Total liabilities
3.73
6.02
8.84
10.8
32.3
14.8
23
56.2
23.9
20.3
Paid-in capital
85.2
184
191
283
338
351
358
366
372
452
Retained earnings
-35.9
-101
-153
-213
-294
-171
-226
-278
-304
-322
Other comprehensive income
-0
0
0
-0.04
0
-0.04
-0.2
Shareholders' equity
49.3
83.4
38.8
70
43.6
180
132
87.8
68.2
131
Total equity
49.3
83.4
38.8
70
43.6
180
132
87.8
68.2
131
Total liabilities and equity
53
89.5
47.6
80.8
75.9
195
155
144
92.2
151
Shares outstanding
9.84
24.6
24.7
54.7
65.7
70.4
70.5
70.7
71
130
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-22.4
-64.8
-52
-60.5
-81
123
-54.2
-52.3
-26.4
-17.4
Depreciation and amortization
0.06
0.08
0.14
0.26
0.31
0.24
0.51
0.57
0.61
0.27
Stock-based compensation
3.64
6.4
7.06
5.21
7.53
5.05
6.56
7.29
6.28
4.81
Deferred income tax
5.8
Cash from operations
-17.8
-31.5
-45.6
-51.1
-51.6
119
-55.2
-45.8
-56
-38.3
Capital expenditures
-0.03
-0.04
-0.03
-0.06
-0.13
-0.18
-1.22
-0.04
-0.07
0
Purchases of investments
-50
-34.8
-9.96
0
-173
-112
-73.2
-91.9
Sales and maturities of investments
45
5
45
0
Cash from investing
-0.19
-0.05
-5.36
-30
34.6
-1.82
-87.9
-2.58
54.6
-49.9
Stock issued
0.03
0.11
64.1
46.7
0
0.18
0.54
0.62
0.09
Cash from financing
-0.01
66.7
0.29
86.5
47.1
0.9
0.18
30.5
0.62
75.2
Net change in cash
-18
35.2
-50.6
5.41
30.1
118
-143
-17.8
-0.74
-13.1
Free cash flow
-17.8
-31.5
-45.6
-51.1
-51.7
118
-56.5
-45.8
-56
-38.3
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.40 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-3,687.0%
Operating income / revenue.
EBITDA margin
-3,681.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-2,179.0%
Pre-tax income / revenue.
Net margin
-2,179.0%
Net income / revenue.
Operating cash flow margin
-3,460.0%
Cash from operations / revenue.
Return on equity (ROE)
-16.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-14.9%
Net income / average total assets.
Return on invested capital (ROIC)
-23.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
2,122.0%
Research and development expense / revenue.
Stock-based pay / revenue
302.0%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
5.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
1,181.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
69.0%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-10.5%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
91.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-0.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
24.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
63.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-0.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
14.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
12.4x
Current assets / current liabilities.
Quick ratio
11.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
11.7x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/S
296x
Market cap / revenue.
P/B
2.23x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.23x
Market cap / tangible book value, when positive.
EV/Sales
222x
Enterprise value / revenue.
Earnings yield
-7.4%
Net income / market cap (the inverse of P/E).
What was Ovid Therapeutics Inc.'s revenue in fiscal 2025?
Ovid Therapeutics Inc. reported revenue of $7.3M for fiscal 2025, 1,181.3% higher than the year before.
Was Ovid Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of $17.4M.
How much free cash flow did Ovid Therapeutics Inc. generate in fiscal 2025?
Cash from operations of $38.3M minus capital expenditures of $0.0 left free cash flow of -$38.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.